News Filter by: Industry Team AutomotiveEnergyFood & BeverageHealth Care Hospitality & LeisureLife SciencesManufacturingMaritime RetailSportsTechnology Practice Area Corporate All CorporateEmployee Benefits & Executive CompensationEnvironmentalEstates & TrustsFinanceInsurance Private Equity & Venture CapitalReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactions Government Solutions All Government SolutionsExport Controls & National SecurityFDA RegulatoryFederal & State Energy RegulatoryFreight & Commuter RailGovernment Procurement Immigration, Nationality & Consular LawNHTSA & Motor Vehicle SafetyPolitical LawPublic PolicyState Attorneys GeneralStrategic Communications Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalCybersecurityElectronicsGreen Energy TechnologiesIP Asset Management IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPTAB TrialsTechnology Transactions & OutsourcingTrademark, Copyright & Advertising Counseling International All InternationalChinaEurope IsraelJapanMexico Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Law, Finance & Class ActionDistribution & Franchise Energy LitigationGovernment Enforcement Defense & InvestigationsInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Office AustinBostonChicagoDallasDenverDetroitHoustonJacksonville Los AngelesMadisonMexico CityMiamiMilwaukeeNew YorkOrlandoSacramento San DiegoSan FranciscoSilicon ValleyTallahasseeTampaTokyoWashington, D.C. Topic Big DataCuba Foreign Corrupt Practices Act (FCPA)Health Care Reform Telemedicine In the News Press Releases Media Contact Jill Chanen Public Relations Manager jchanen foley.com 312.832.4745 1234next 18 April 2019 Rosen Comments on Korean Pharma Companies Doing Business in the U.S. –Korea Biomedical Review Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America. 22 March 2019 Foley Represents Milwaukee Bucks in Development of High-Tech, Adjustable Thermal Bench Foley & Lardner LLP represented the NBA’s Milwaukee Bucks in connection with its development of a high-tech, adjustable thermal bench for its players. 21 December 2018 Pirozzolo-Mellowes Named to the Board of The Medical College of Wisconsin Partner Jan Pirozzolo-Mellowes was named to the Board of Trustees of The Medical College of Wisconsin. 19 December 2018 Geilfuss, Faget Comment on Implications of Possible ACA Ruling –Modern Healthcare Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional. 01 November 2018 Foley Receives 29 National Tier 1 Practice Rankings in 2019 U.S. News – Best Lawyers Foley & Lardner is pleased to announce that it received 29 national Tier 1 rankings and 131 metropolitan Tier 1 rankings in the 2019 edition of U.S. News – Best Lawyers “Best Law Firms.” 15 August 2018 Foley Attorneys Recognized In The Best Lawyers in America 2019 List –Best Lawyers Foley announced today that 27 of its attorneys earned Best Lawyers 2019 “Lawyer of the Year” recognition in their respective practice areas. In addition, 242 of the firm’s attorneys in 19 offices have been listed in The Best Lawyers in America 2019. 01 August 2018 Foley Gardere Adds Technology Transactional Partner to Dallas Office Foley Gardere announced today that Dr. Guy Birkenmeier has joined the firm’s Technology Transactions & Outsourcing Practice as a partner in the Dallas office. 25 July 2018 Rosen Comments on FDA Plan to Facilitate Biosimilars –Regulatory Focus Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion. 15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products. 26 April 2018 Koski Comments on Prospects for Prescription Drug Legislation –Pharmaceutical Technology Partner Katy Koski was quoted in a Pharmaceutical Technology article, “CREATES Act Dropped But May Still See Progress,” about the chances that legislation aimed at lowering the costs of prescription drugs will be taken up by Congress this year. 1234next Search News Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared
18 April 2019 Rosen Comments on Korean Pharma Companies Doing Business in the U.S. –Korea Biomedical Review Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America.
22 March 2019 Foley Represents Milwaukee Bucks in Development of High-Tech, Adjustable Thermal Bench Foley & Lardner LLP represented the NBA’s Milwaukee Bucks in connection with its development of a high-tech, adjustable thermal bench for its players.
21 December 2018 Pirozzolo-Mellowes Named to the Board of The Medical College of Wisconsin Partner Jan Pirozzolo-Mellowes was named to the Board of Trustees of The Medical College of Wisconsin.
19 December 2018 Geilfuss, Faget Comment on Implications of Possible ACA Ruling –Modern Healthcare Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
01 November 2018 Foley Receives 29 National Tier 1 Practice Rankings in 2019 U.S. News – Best Lawyers Foley & Lardner is pleased to announce that it received 29 national Tier 1 rankings and 131 metropolitan Tier 1 rankings in the 2019 edition of U.S. News – Best Lawyers “Best Law Firms.”
15 August 2018 Foley Attorneys Recognized In The Best Lawyers in America 2019 List –Best Lawyers Foley announced today that 27 of its attorneys earned Best Lawyers 2019 “Lawyer of the Year” recognition in their respective practice areas. In addition, 242 of the firm’s attorneys in 19 offices have been listed in The Best Lawyers in America 2019.
01 August 2018 Foley Gardere Adds Technology Transactional Partner to Dallas Office Foley Gardere announced today that Dr. Guy Birkenmeier has joined the firm’s Technology Transactions & Outsourcing Practice as a partner in the Dallas office.
25 July 2018 Rosen Comments on FDA Plan to Facilitate Biosimilars –Regulatory Focus Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
26 April 2018 Koski Comments on Prospects for Prescription Drug Legislation –Pharmaceutical Technology Partner Katy Koski was quoted in a Pharmaceutical Technology article, “CREATES Act Dropped But May Still See Progress,” about the chances that legislation aimed at lowering the costs of prescription drugs will be taken up by Congress this year.